Investor Eye
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Investor Eye: Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments
Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.

Investor Eye: Medtech Innovator’s Accelerator Is Catching Up With Pharma
Each year, Medtech Innovator whittles down a vast number of applicants to a relatively succinct shortlist of companies. Paul Grand, Medtech Innovator’s CEO, spoke to Medtech Insight about this process, as well as some of the broader trends impacting investment in medtech.

Investor Eye: Intuitive Surgical Hops, Skips, And Jumps Into VC
When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.

Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.

Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future
Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.

Getting Personal With De Oro Devices’ Sidney Collin: ‘There’s A Lot Of Learning That Needs To Happen’
In this new series titled Getting Personal, we talk to new and veteran executives about the trials and tribulations in running a company while exploring their own motivations and passions. In this first edition, we talk to Sidney Collin, co-founder and CEO of De Oro Devices. Collin invented NexStride, a portable device to help overcome freezing of gait in Parkinson’s disease patients, while studying biomedical engineering at the California Polytechnic State University in 2018.

Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.

‘The Story That No One Likes To Hear’: Investors Looking For Surer Bets In Health Tech After Record 2021
A panel of investors and leaders in healtech expects investment in health tech to decline, but still foresees opportunities for companies working on solutions that will transform overall health care such as AI, ML, mental health and health equity.

‘Investee’ Eye: Quanta CEO’s Perspective Of Seeking And Obtaining $245m Raise
Quanta CEO John Milad outlines the transitional stage where a company begins to seek large-scale funding for the first time, and debates market valuations.

Investor Eye: Endeavour Vision Highlights Humanity Of Medtech, Invests In Unmet Needs
Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.

Investor Eye: Novalis Embraces Early Investment And Enabling Technology
Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.

Investor Eye: Octopus Ventures Tackles Tough, Taboo Problems In Health Care
In an interview with Medtech Insight, Octopus Ventures partner Pooja Sikka explained the approach Octopus takes to investments, and the key challenges the fund wants to address.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.